

NCT	Phase	Indikation	Intervention	Sponsor	Status
NCT03681951	P2	Neoplasms, Pancreatic	GSK3145095	GlaxoSmithKline	Terminated
NCT03655678	P1, P2	Hemoglobinopathies	CTX001	Vertex Pharmaceuticals Incorporated, Crispr Therapeutics	Recruiting
NCT03745287	P1, P2	Sickle Cell Disease	CTX001	Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics	Recruiting
NCT04035434	P1, P2	Lymphoma	CTX110	CRISPR Therapeutics AG	Recruiting
NCT03538613	P1, P2	Gastrointestinal Epithelial Cancer	CISH inactivated TIL	National Cancer Institute (NCI)	Withdrawn
NCT03166878	P1, P2	B Cell Leukemia, B Cell Lymphoma	UCART019	Chinese PLA General Hospital	Recruiting
NCT03398967	P1, P2	B Cell LeukemiaB Cell Lymphoma	Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells	Chinese PLA General Hospital	Recruiting
NCT03044743	P1, P2	Advanced stage malignancies	PD-1 knockout EBV-CTL cells	Yang Yang	Recruiting
NCT03872479	P1, P2	Retinal Degeneration	AGN-151587	Allergan, Editas Medicine, Inc.	Recruiting
NCT03057912	P1	Human Papillomavirus-Related Malignant Neoplasm	TALEN, CRISPR/Cas9	First Affiliated Hospital, Sun Yat-Sen University Jingchu University of Technology	Unknown
NCT03545815	P1	Solid Tumor, Adult	anti-mesothelin CAR-T cells	Chinese PLA General Hospital	Recruiting
NCT03399448	P1	Multiple Myeloma, Melanoma	NY-ESO-1 redirected autologous T cells with CRISPR edited	University of Pennsylvania Parker Institute for Cancer Immunotherapy, Tmunity Therapeutics	Recruiting

			endogenous TCR and PD-1		
NCT04037566	P1	Leukemia	XYF19 CAR-T cell	Xijing Hospital Xi'An Yufan Biotechnology Co.,Ltd	Recruiting
NCT03728322	P1	Thalassemia	iHSCs treatment group	Allife Medical Science and Technology Co., Ltd.	Recruiting
NCT03747965	P1	Solid Tumor	Mesothelin- directed CAR- T cells	Chinese PLA General Hospital	Recruiting
NCT03690011	P1	T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non- Hodgkin Lymphoma	CD7.CAR/28z eta CAR T cells	Baylor College of Medicine	Recruiting
NCT02863913	P1	Invasive Bladder Cancer Stage IV	PD-1 Knockout T Cells	Peking University	Withdrawn
NCT02867332	P1	Metastatic Renal Cell Carcinoma	PD-1 Knockout T Cells	Peking University	Withdrawn
NCT02793856	P1	Metastatic Non-small Cell Lung Cancer	PD-1 Knockout T Cells	Sichuan University	Active
NCT04074369	Observa tional	Tuberculosis, Pulmonary; Diagnostic Test	CRISPR-based Test	Huashan Hospital	Recruiting
NCT03167450	Observa tional	Sickle Cell Disease		National Human Genome Research Institute (NHGRI)	Suspended
NCT03855631	Observa tional	Kabuki Syndrome 1	Intervention on primary cultured cells	University Hospital, Montpellier	Active
NCT03332030	Observa tional	Neurofibromatosis Type 1	Diagnostic Test: Collection of Stem Cells	Children's Research Institute	Recruiting
NCT02867345	Observa tional	Hormone Refractory Prostate Cancer	PD-1 Knockout T Cells	Peking University	Withdrawn

NCT04122742	Observational	Rubinstein-Taybi Syndrome	Diagnostic screen	University Hospital, Bordeaux	Recruiting
NCT02964481	Observational	Malignant Hyperthermia	Diagnostic screen	Children's Hospital Medical Center, Cincinnati	Recruiting
NCT04178382	N/A	Severe Sepsis; Diagnostic Test: PCR-CRISPR/Cas12a detection	PCR-CRISPR/Cas12a detection	Chinese Medical Association	Recruiting
NCT03164135	N/A	HIV-1-infection	CCR5 gene modification	Affiliated Hospital to Academy of Military Medical Sciences Peking University Capital Medical University	Recruiting
NCT03342547	N/A	Gastrointestinal Infection	Diagnostic screen	Chinese University of Hong Kong	Recruiting
NCT03606486	N/A	Ovarian Cancer	Diagnostic	University of Washington	Recruiting
NCT03081715	N/A	Esophageal Cancer	PD-1 Knockout T Cells	Hangzhou Cancer Hospital	Completed

Datenbankrecherche in clinicaltrials.gov; Suchbegriff «crispr», accessed 10.12.2019